Heptares Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Heptares Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10867)・商品コード:DATA904C10867
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:41
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Heptares Therapeutics Ltd (Heptares) a subsidiary of Sosei Group Corp is a drug discovery company that develops small-molecule drugs. The company develops drugs for targeting G-protein-coupled receptors by utilizing its drug discovery technology platforms. Its technology platforms comprise StaR technology, StaR-driven X-ray crystallography, Biophysical Mapping and StaR fragment screening. Heptares’ products are used in the treatment of Alzheimer’s disease, schizophrenia, binge eating, type 2 diabetes, autism, depression, dyskinesia, migraine treatment, and others. The company partners with other pharma and biotech companies to develop its products. Heptares is headquartered in Welwyn Garden, the UK.

Heptares Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Heptares Therapeutics Raises US$21 Million In Series B Financing 12
Partnerships 13
Heptares Therapeutics Enters into Co-Development Agreement with DyNAbind 13
Heptares Therapeutics Enters into Research Agreement with Imperial College London 14
Heptares Therapeutics Enters into Research Agreement with Juntendo University 15
Heptares Therapeutics and PeptiDream Enter into Agreement 16
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 17
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 18
Jitsubo Enters into Agreement with Heptares Therapeutics 19
Heptares Therapeutics and leadXpro Enter into Agreement 20
Heptares Therapeutics to Form Partnership with Kymab 21
Heptares Therapeutics Enters into Agreement with Pfizer 22
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 23
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 24
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 25
Heptares Therapeutics Extends Collaboration with the UK Medical Research 26
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 27
Licensing Agreements 28
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 28
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 29
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 30
Acquisition 31
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 31
Sosei Acquires Heptares Therapeutics for USD400 Million 32
Heptares Therapeutics Ltd – Key Competitors 33
Heptares Therapeutics Ltd – Key Employees 34
Heptares Therapeutics Ltd – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Government and Public Interest 36
Jan 04, 2018: Heptares Scientists Solve Structure of Complement C5a Receptor, an Important Drug Target for Inflammatory and Neurodegenerative Diseases, and Cancer 36
May 31, 2017: Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 37
Product News 38
May 31, 2017: Sosei Subsidiary Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 38
05/18/2017: Heptares to Receive US$5 Million Milestone Payment from Teva 39
Clinical Trials 40
Apr 05, 2017: Heptares to Receive US$12 Million Milestone Payment from Astrazeneca 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heptares Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Heptares Therapeutics Raises US$21 Million In Series B Financing 12
Heptares Therapeutics Enters into Co-Development Agreement with DyNAbind 13
Heptares Therapeutics Enters into Research Agreement with Imperial College London 14
Heptares Therapeutics Enters into Research Agreement with Juntendo University 15
Heptares Therapeutics and PeptiDream Enter into Agreement 16
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 17
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 18
Jitsubo Enters into Agreement with Heptares Therapeutics 19
Heptares Therapeutics and leadXpro Enter into Agreement 20
Heptares Therapeutics to Form Partnership with Kymab 21
Heptares Therapeutics Enters into Agreement with Pfizer 22
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 23
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 24
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 25
Heptares Therapeutics Extends Collaboration with the UK Medical Research 26
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 27
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 28
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 29
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 30
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 31
Sosei Acquires Heptares Therapeutics for USD400 Million 32
Heptares Therapeutics Ltd, Key Competitors 33
Heptares Therapeutics Ltd, Key Employees 34
Heptares Therapeutics Ltd, Subsidiaries 35

List of Figures
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Heptares Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10867)販売に関する免責事項を必ずご確認ください。
★調査レポート[Heptares Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆